Kanova Biopharma

Kanova Biopharma was founded in November 2015. Based on cutting-edge scientific research from around the world, the company is committed to the development of drugs targeting novel pathways or innovative combinations for cancer and autoimmune inflammatory diseases, with a focus on precision innovation. It leads the research and development of innovative immunotherapy antibody drugs. Currently, the company has a rich pipeline of products for cancer immunotherapy and autoimmune diseases. In 2017, Kanova Biopharma's first antibody drug for the treatment of autoimmune diseases was licensed to Livzon MabPharm Inc. for development in a milestone deal, and it received clinical trial approval in February 2020.